SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

The FDAs accelerated approval of Inovios competing RRP treatment has put pressure on Precigens PAPZIMEOS franchise. Traders debate whether the rivals treatment advantages will erode sales or whether PAPZIMEOSs first-mover position, established commercial uptake, and full approval provide a durable edge.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken after early 2027 has triggered a sharp selloff and concerns about pricing and revenue. Traders disagree over how much weight to give DaVitas preliminary outlook, with some citing CMSs finalized initial 2027 rate and arguing the warning does not establish a sustained decline.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly earnings beat, led by strong refining results amid tight diesel and fuel supplies, is the main focus; traders are broadly positive, while some question whether the rally can continue and whether elevated refining margins will last.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings beat, supported by Eylea HD and Sanofi collaboration growth, has driven a sharp share-price breakout to multiyear highs. Traders are broadly celebrating the results, while some are watching whether the rally can hold amid wider market weakness.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,942,077.7905448. The last known price of Zcash is 1,263.32437248 USD and is up 2.82 over the last 24 hours. It is currently trading on 668 active market(s) with $1,115,981,976.30 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp rally and relative strength versus the broader crypto market are driving attention, with traders highlighting its privacy-focused use case and arguing it has held up amid Binance-hack-related market jitters. Bullish traders see accumulation and potential further gains, while skeptics warn the move may be overextended and point to volatile pullbacks.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

FLY is drawing attention amid a sharp selloff that traders largely link to broader market and space-sector weakness, with many saying they see no new company-specific bad news. Some also worry about uncertainty around Alpha launch timing and want a firm update, while bullish traders view the drop as an opportunity.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak next-quarter outlook after its quarterly reportamid soft PC demand and manufacturing constraintstriggered a steep selloff and analyst downgrades. Traders are divided between calling the drop an overreaction and buying the dip, and warning that further losses may follow as Intels turnaround faces execution challenges.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths quarterly earnings beat and raised full-year outlook, supported by an improved medical care ratio, are the main focus. Traders are divided over why shares have struggled to sustain gains despite the results, with ongoing scrutiny of medical costs and volatile price action fueling both recovery bets and bearish calls.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A quarterly earnings beat and higher revenue outlook, powered by strong demand for Mounjaro and Zepbound, drove Lilly shares to record highs and prompted bullish reactions and analyst upgrades. Traders also debated the high valuation and lower profit guidance tied to acquisition charges, while some flagged Foundayos slower launch versus Novo Nordisks oral offering.

Coeur Mining, Inc. engages in the well-diversified, growing precious metals producer with a focus on generating sustainable, high-quality cash flow and returns from a balanced, prospective asset base in mining-friendly jurisdictions along with commitment to exploration and expansions. It operates through the following segments: Palmarejo, Rochester, Kensington, Wharf and Silvertip. The Palmarejo segment includes a gold-silver complex. The Rochester segment operates an open pit heap leach silver-gold mine in northwestern Nevada. The Kensington segment relates to an underground gold mine located north of Juneau, Alaska. The Wharf segment focuses on an open pit heap leach gold mine located near Lead, South Dakota. The Silvertip segment silver-zinc-lead exploration located in the state of Sonora in northern Mexico. The company was founded in 1928 and is headquartered in Chicago, IL.

Coeur Mining Inc

Falling gold and silver prices are weighing on miners, with traders noting CDEs steep decline and recent 52-week low. The community is split between expecting further downside and buying the dip, while some point to put-heavy options activity as a sign of caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.41, signifying a -13.01% move from its prior day's close.

Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Humacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.

Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.

Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF continues its investigation into Humacyte, Inc. (NasdaqGS: HUMA) (Humacyte or the Company). On August 9, 2024, the company announced that the Food and Drug...

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Humacyte Inc

HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Humacyte said it will use the money to support sales of its recently FDA-approved product Symvess and prepare an application for FDA approval of its vessel in dialysis patients, among other things.&nbsp;</li><li>The company also announced top-line results from its late-stage study in female dialysis patients.</li><li>Because the main goal of the study was met, Humacyte said it is stopping further enrollment and will follow the current patients.</li></ul>Humacyte Inc. (HUMA) shares fell 11% in after-hours trading on Wednesday, after the company announced a proposed underwritten public offering of common stock in addition to releasing early results from a key clinical trial for its experimental blood vessel product.The size and price of the stock offering were not disclosed. Humacyte said it will use the money to support sales of its recently FDA-approved product Symvess, prepare an application for FDA approval of its vessel in dialysis patients, advance other research, and cover day-to-day operations.<h2 class="st-heading-2">Trial Outcomes</h2>Earlier the same day, Humacyte announced top-line results from its late-stage study in female dialysis patients. In an early look at the first 80 patients, those who received the company’s lab-grown blood vessel (called ATEV) averaged 220 days without a temporary dialysis catheter over 12 months. Patients who got the standard vein connection (an AV fistula) averaged only 129 catheter-free days — a difference of 91 days that was highly statistically significant.Because the main goal of the study was met, Humacyte said it is stopping further enrollment and will follow the current patients. The company plans to file for FDA approval of ATEV for use in adult dialysis patients later this year.Safety results also looked better for ATEV. Infection rates were much lower (6 per 100 patient-years versus 23 for fistulas), with no study-related infections in the ATEV group. No vessel ruptures occurred in either arm.“We are excited to announce these positive results,” said Shamik Parikh, Humacyte’s chief medical officer. “Patients receiving ATEV had an average of three extra months without a catheter compared to the standard option — a very meaningful improvement for female patients who often have fewer good choices.”Humacyte is a commercial-stage biotech company that creates ready-to-use, lab-grown human tissues. It won FDA approval for its first product, Symvess, for emergency vascular repairs in late 2024 and launched it in early 2025. ATEV is still considered experimental for dialysis use.<h2 class="st-heading-2">How Did HUMA Retail Traders React?</h2>On Stocktwits, retail sentiment around HUMA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels. &nbsp;A Stocktwits user opined that the stock’s trajectory doesn't look as bad as it could have been.<stembedurl>https://www.stocktwits.com/MeetMillz732/message/656061935</stembedurl>Another user applauded the trial results and dismissed the impact of the stock offering.<stembedurl>https://www.stocktwits.com/JayCon888/message/656065815</stembedurl>A third user expressed optimism for Humacyte's product being approved for dialysis patients.<stembedurl>https://www.stocktwits.com/WallStSweeper/message/656061210</stembedurl>According to data from Koyfin, four of the five analysts covering HUMA rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The 12-month average price target on the stock is $1.90, representing a potential upside of about 42% from the last close.<a href="https://stocktwits.com/symbol/HUMA">HUMA stock</a> has gained 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-watches-spacex-ipo-while-cheapest-cybertruck-hits-driveways-after-long-wait/cZ06Dj7R7cf">TSLA Stock Watches SpaceX IPO While Cheapest Cybertruck Hits Driveways After Long Wait</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

The size and price of the stock offering were not disclosed.

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

HUMA News